Below we presented the list of 5 best small-cap biotech stocks under $10 in 2021. For our detailed discussion as well as a more comprehensive list please see 10 Best Small-Cap Biotech Stocks Under $10 in 2021.
At Insider Monkey we leave no stone unturned when looking for the next great investment idea. For example, lithium mining is one of the fastest growing industries right now, so we are checking out stock pitches like this emerging lithium stock. We go through lists like the 10 best hydrogen fuel cell stocks to pick the next Tesla that will deliver a 10x return. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. You can subscribe to our free daily newsletter on our homepage. Keeping this in mind let’s take a look at the best small-cap biotech stocks under $10:
5. Assembly Biosciences Inc. (NASDAQ: ASMB)
No of Hedge Funds: 22
Total Value of HF Holdings: $195 Million
Assembly Biosciences Inc is a clinical-stage biotechnology company that primarily works on the treatment of hepatitis B (HBV). It is focusing on chronic HBV and novel oral biotherapeutic candidates for the treatment of disorders associated with the microbiome. In December 2020 the company announced that it will wind-down its microbiome program to focus on the advancement of its pipeline of novel core inhibitors for chronic HBV.
In the third quarter, the company posted a GAAP EPS of -$0.09, above the Street’s estimates by $0.69. Revenue in the quarter jumped 718% to reach $34.61 million, beating the Street’s estimates by $28.17 million.
4. Dynavax Technologies Corp. DVAX (NASDAQ: DVAX)
No of Hedge Funds: 23
Total Value of HF Holdings: $58 Million
Dynavax makes treatment for human body’s immune system stability. The company works on adjuvant vaccine for hepatitis B by utilizing expertise of Toll-like Receptor (TLR) biology. It is known for Hepatitis B vaccine HEPLISAV-B.
In January 2021, Dynavax Technologies Corporation announced that the first participant has been dosed in the Phase 2 clinical trial evaluating MVC’s COVID-19 vaccine candidate, MVC- COV1901. MVC-COV1901 is a subunit vaccine with recombinant S-2P antigen adjuvanted with CpG 1018 supplied by Dynavax.
3. WAVE Life Sciences Ltd. WVE (NASDAQ: WVE)
No of Hedge Funds: 24
Total Value of HF Holdings: $163 Million
WAVE Life Sciences deals in nucleic acid therapeutics. The company is developing a portfolio of stereo pure drug candidates that target underlying rare genetic diseases in human body. In the third quarter, net loss came in at $33.10 million, while revenue in the period totaled $3.45 million.
2. Kadmon Holdings LLC KDMN (NASDAQ: KDMN)
No of Hedge Funds: 24
Total Value of HF Holdings: $304 Million
The company is engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical needs. Earlier in January, the company’s shares rallied after hedge fund manager Steve Cohen’s Point72 Asset Management reported a 5.3% stake in the company, representing about 9.05 million shares.
1. IVERIC bio-Inc. ISEE (NASDAQ: ISEE)
No of Hedge Funds: 26
Total Value of HF Holdings: $278 Million
Iveric Bio makes treatment for retinal diseases with significant unmet medical needs. In April 2020, the company said the FDA granted Fast Track designation to Zimura, the company’s C5 inhibitor for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). In the third quarter, ISEE posted Q3 GAAP EPS of -$0.27, missing the Street’s forecast by $0.05.
You can also read 15 Biggest Companies with Gay CEOs and 15 Biggest Oil Refining Companies.
